Clinical trials are crucial to learning and are required for commercial licensing of therapeutic drugs. Field trials that are required by FDA to licence treatments are called effectiveness studies.
- Effectiveness studies are placebo or "active" controlled studies using natural disease cases.
- Effectiveness studies that were used to license drugs are available to the public. Search using the key words "Freedom of Information Summary (fill in the drug name here).
- A client consent form is required for this type of study.
Some of our trials are designed to gather data from animals suffering from EPM or EPM related diseases, they are potential clinical benefit studies.
- Potential benefit studies aren't always controlled studies.
- Potential benefit studies are used to support the FDA submissions.
- A veterinarian is involved in this type of study.
Please read the entrance requirements for each study. Studies vary, some are placebo controlled or are designed to use an active control (the "placebo" is a licensed EPM medication). Some studies are designed to show potential benefits of the treatment and are uncontrolled. A PLACEBO CONTROLLED STUDY WILL BE CLEARLY EXPLAINED BEFORE YOU ENROLL. YOU MAY NOT ENTER A PLACEBO CONTROLLED STUDY WITHOUT SIGNING AND RETURNING THE INFORMATION FORM.
Pathogenes donates services and medications to diagnose and treat horses in need. Starting in 2018, we require a copy of the tax exempt status of the organization (rescue) associated with the horse. To participate in our rescue program please submit:
- A serum sample,
- A synopsis of the horses history and prior treatment,
- Brief description of the need,
- A copy of the 501 (c) 3 status of the organization.
Horses that don't require a 501 (c) 3:
- Miniature horses are exempt from the 501 (c) 3 status requirement,
- Zoo animals are exempt from the 501 (c) 3 status requirement,
- Horses with penile paralysis, urinary incontinence, bowel stasis may be exempt from the 501 (c) 3 status.
OROGIN FIELD EFFECTIVENESS STUDY
The protocol is designed to determine the difference between treatment success rate between Orogin and a licensed agent, Protazil, in a non-inferiority study.
- All adult horses of any breed of either sex may enroll;
- Clinical signs characterized by a gait assessment score of > 2 and < 5;
- A diagnosis of EPM supported by IFAT testing, positive serum: CSF ratio <100;
- A diagnosis of EPM supported by additional diagnostic work up to rule out other causes of ataxia;
- Has not been treated for EPM within 60 days of enrollment.
Exclusion criteria are the same as those that are found in the Freedom of Information Summary for Protazil. FIS Protazil. Veterinarians are invited to inquire and receive the protocol for this study. Please provide the Owner Consent that is required for participation and the ability to receive medication. Potential Field Investigators should read VICH9 outlining the responsibilities to participate in this GLP study.
The medication used in the Orogin Field Effectiveness trial contains a new animal drug for use in investigational animals in clinical trials. These drugs are not to be used in humans. Edible products of investigational animals are not to be used for food unless authorization has been granted by the US FDA or USDA.
NEUROQUEL FIELD EFFECTIVENESS STUDY
This study has FDA concurrence. The study objectives are intended to evaluate the effectiveness of NeuroQuel over a placebo for the treatment of residual or recurrent clinical signs of EPM. The entrance requirements are:
- A horse between 2-20 years weighing at least 600 pounds of either sex;
- Must have an original diagnosis of EPM that includes:
- A positive test for EPM (CSF testing required);
- Treated for EPM using an FDA approved treatment within 90 days of enrollment;
- Residual signs of EPM that include a gait assessment score (GAS) of 2 by the end of treatment or that recurred after the cessation of therapy.
A signed consent form must be completed for this study. NQ Owner Consent. Veterinarians are invited to call and receive the protocol for this study.
The medication used in the NeuroQuel Field Effectiveness study contains a new animal drug for use in investigational animals in clinical trials. These drugs are not to be used in humans. Edible products of investigational animals are not to be used for food unless authorization has been granted by the US FDA or USDA.
NEUROQUEL FOR THE CONTROL OF SIGNS OF POLYNEURITIS EQUI
This study protocol is under review with FDA. The study is intended to evaluate the effectiveness of NeuroQuel for the control of clinical signs associated with polyneuritis equi (PNE). The study population includes adult horses 2-30 years old weighing at least 605 pounds, of either sex. To be eligible a horse must be:
- between 2-30 years weighing at least 605 pounds of either sex;
- Must have a presumptive diagnosis of PNE that includes:
- A positive serum test for PNE (CSF testing not required);
- A negative serum test for EPM (CSF not required);
- A Clinical Score of 2 or greater with clinical signs consistent with PNE
- No recent history of trauma or respiratory disease or rabies
- A serum vitamin E level of >1.5 micrograms/ml
A signed Owner Consent form must be completed for this study.
Veterinarians are invited to call and review the protocol for this study.
EPM PREVENTION STUDY (completed)
Useful link: module 29 Veterinary Feed Directive
Veterinary Feed Directive PDF form for veterinarians
For the veterinarian: some things you should know:
Any medication provided in a Clinical Trial listed above will have package labeling or package insert labeling that includes contact information to report the response to treatment including side effects. Adverse events or drug related side effects should be brought to the attention of your veterinarian. You may report adverse events directly to Pathogenes by phone, email, or using the Case Analysis form for Horse Owners. Please email supporting information such as examinations by veterinarians, blood analysis, or any treatments that were administered for the abnormal signs.